Shapuaisi

Zhejiang Shapuaisi Pharmaceutical Co., Ltd. was established in 1978 as a comprehensive pharmaceutical enterprise specializing in the research, production, and operation of medicines. It successfully listed on the Shanghai Stock Exchange Main Board (Stock Code: 603168) on July 2, 2014. In October 2020, it successfully acquired Taizhou Obstetrics and Gynecology Hospital affiliated with Nantong University, officially stepping into high-quality development in "medicine + healthcare," becoming a large-scale health enterprise focusing on medical services, pharmaceutical production, sales, and research, particularly in ophthalmology, obstetrics, and pediatrics. The company currently owns subsidiaries such as Zhejiang Shapuaisi Pharmaceutical Sales Co., Ltd., Zhejiang Shapuaisi Pharmacy Chain Co., Ltd., and Taizhou Women and Children's Hospital Co., Ltd. Hard work builds strength, and strength forges excellence. Since its establishment, the company has been recognized six times as a "High-tech Enterprise" and has successively been awarded titles such as "National Torch Plan Key High-tech Enterprise," "Zhejiang Province Standard Innovation Enterprise," and "Top 100 Most Investment-worthy Enterprises in Zhejiang Province." It has also repeatedly received honors such as "Top 100 Comprehensive Strength Industrial Enterprises in China's Chemical Pharmaceutical Industry," "Excellent Product Brand in Various Categories of China’s Chemical Pharmaceutical Industry," "Excellent OTC Product Brand in China's Chemical Pharmaceutical Industry," and the "Social Responsibility Precision Poverty Alleviation Award." The company’s main products include anti-cataract medications like "Shapuaisi" eye drops—a National Class II new drug for ophthalmology—and anti-glaucoma medication "Da Liang" eye drops, both of which are included in the "National Torch Plan Projects." Its exclusive domestic product is the antibacterial Class II new drug, methanesulfonate pazufloxacin eye drops. Additionally, the company covers niche therapeutic areas including antimicrobial drugs (cephalosporins), antimicrobial drugs (quinolones), and drugs regulating water, electrolyte, and acid-base balance, with more than ten chemical and traditional Chinese medicine formulations, including large-volume injections, oral solutions, tablets (including cephalosporins), and hard capsules (including cephalosporins). Social responsibility comes first in public welfare. Shapuaisi actively assumes social responsibilities and engages in charitable causes. In recent years, the company has launched a series of large-scale public welfare initiatives such as "Enlightening China," "Concentric Circle · Love for Xiadang," and "Celebrating a Century, Walking a Hundred Miles—Shapuaisi Charity Staying True to Our Original Aspiration," while establishing the "Pu Ai Tong Xin Public Welfare Special Fund," giving back to society through concrete actions and spreading positive energy, continuously contributing to the development of China’s public welfare sector.